Skip to content
Company Analysis

Cerus Corporation CERS

A comprehensive view of key metrics, scores, and financial health for Cerus Corporation

Overview of Cerus Corporation

CERS NGM
Healthcare Medical Devices Framework: Medical Devices & Diagnostics Small Cap
Cerus Corporation (CERS), is a Small Cap company, in the Medical Devices industry, last closed at $3.02, about 53.0% overvalued vs fair value, +130.5% 1Y return, ranked 477/1145 in sector.
Metrics Rev Growth 14.4% ROE -26.0% Gross Margin 54.5%
USD 3.02
-3.21%
(Delayed)
• Vol 90d: 70.8%
52-Week Range
Market Cap
$631.16M
Enterprise Value
$700.67M
Overall Score
View breakdown
Overall
Growth
Fair
Profitability
Good
Health
Fair
Efficiency
Fair
Valuation
Fair
Growth
Fair
Profitability
Good
Health
Fair
Efficiency
Fair
Valuation
Fair
Completeness: 82%
Confidence: 84%
Updated: Jul 5
Top Beats

Quick Facts

Website https://www.cerus.com
HQ Concord, CA
Employees 614
Fiscal year Dec 31

Next Events

No upcoming events available.

Fair Value Snapshot

Bear Base Bull
$1
$1
$2
Current: $3.02 -53% vs base

Engine Room Money Flow™

Small Cap

Medical Devices & Diagnostics - Where revenue goes and how value is created

Flow Steps
Total Revenue
$206.1M
14.3%%
Gross Profit
$112.3M
12.8%%
Operating Income (GAAP)
$-8.7M
39%%
EBITDA
$-5.5M
45%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Medical Devices & Diagnostics

Quality & Reliability Indicators

Gross Margin
54.5%
Good

Gross Profit / Revenue — primary moat signal for MedTech. ≥65% indicates IP-protected consumables with strong pricing power.

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
6
Active Leaks
1/6
Improving
1
High Impact
4
Critical
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Moat Analysis Medical Devices & Diagnostics

Competitive Advantage Assessment

Evaluating Cerus Corporation's durable competitive advantages across 6 defense dimensions

Overall Moat Strength
57
/100
Moderate
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power & Consumable Moat

Moderate
62
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Healthcare: MedTech (Devices & Supplies) vs Industry Peers 87% Coverage
Trade-Off Triangle Visualization A ternary plot showing CERS's balance between Growth (34.5%), Profitability (35.3%), and Safety (30.2%). Growth 35% Safety 30% Profitability 35%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

53th percentile vs peers
54
Key Signals
Rev Growth YoY 14.3% 66p Revenue CAGR 3Y 8.3% 54p EPS Growth YoY 27.7% 53p Asset Growth YoY 10.4% 72p TSR -62.5% 5p
Strengths
  • Cash Flow to Debt Ratio in top 20% of peers (4.80, 94th percentile)
Risks

No significant risks identified for this axis.

Profitability

55th percentile vs peers
55
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

47th percentile vs peers
47
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Cerus Corporation.

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$1.42
- - -
-53.0% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000